Peri-operative chemotherapy with or without bevacizumab in operable oesophagogastric adenocarcinoma (UK Medical Research Council ST03): primary analysis results of a multicentre, open-label, randomised phase 2–3 trial

David Cunningham, Ruth E. Langley, Stephen Falk et al.|The Lancet Oncology|2017

Cited by 286